Surfactant Therapy in Severe Meconium Aspiration Syndrome
Neonatal Medicine
;
: 318-322, 2013.
Article
in Korean
| WPRIM
| ID: wpr-97614
ABSTRACT
Meconium is a strong inactivator of pulmonary surfactant. The deficiency of surfactant or surfactant dysfunction may contribute to respiratory failure in a wide group of disorders, including meconium aspiration syndrome (MAS). We reviewed the effect of pulmonary surfactant therapy for severe MAS in ours as well as other countries. In general, surfactant therapy improves pulmonary oxygenation (oxygenation index or arterial/alveolar oxygen tension) and reduces the requirement for ventilation, and oxygen supplementation or hospitalization time. However, its effects on mortality and pulmonary or extrapulmonary complications are variable. In Korean studies, outborn infants are five times more common than inborn infants; therefore, the initial hospital care at delivery including adequate tracheal suctioning is important to improve the outcome of patients with severe MAS. To confirm the effect of surfactant therapy in MAS, additional well-designed, multicenter, randomized, controlled trials are needed. In addition, determining the optimal type of surfactant therapy (bolus, lavage, or combined) and the appropriate dose and duration of therapy is important.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Oxygen
/
Respiratory Insufficiency
/
Suction
/
Ventilation
/
Pulmonary Surfactants
/
Meconium Aspiration Syndrome
/
Hospitalization
/
Therapeutic Irrigation
/
Meconium
Type of study:
Controlled clinical trial
Limits:
Humans
/
Infant
/
Infant, Newborn
Language:
Korean
Journal:
Neonatal Medicine
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS